Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – LS:A0LCUL
This article displays the Enterprise Value to EBITDA forward for Catalyst Pharmaceuticals, Inc. (A0LCUL) on Lang & Schwarz Tradecenter. The page shows the current market status as closed with no trades recorded. It also outlines various financial and community data points available for the company.
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Catalyst Pharmaceuticals Inc (CPRX), noting its current earnings forecast score of 6.67, ranking 126th in the Pharmaceuticals industry. Analysts have an average price target of $34.00 for CPRX, with most recommending a "Buy" trend. The expected revenue for the next quarter is $156.31M, with an anticipated EPS of $0.48.
Catalyst Pharmaceuticals Inc (CPRX) Income Statement
This article provides a detailed income statement for Catalyst Pharmaceuticals Inc (CPRX), presenting quarterly and annual financial data spanning several fiscal years. It includes key financial metrics such as total revenue, cost of revenue, operating expenses, R&D expenses, operating profit, income before tax, net income, and earnings per share. The document also features an FAQ section to help users understand how to interpret the income statement and notable financial figures for fiscal year 2025.
Catalyst Pharmaceuticals Inc (CPRX) Cash Flow
This article provides a detailed cash flow statement for Catalyst Pharmaceuticals Inc (CPRX), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow terms and offers insights into CPRX's financial performance, such as its operating cash flow, capital expenditures, and free cash flow for recent periods.
Catalyst Pharmaceuticals, Inc. Revenue Breakdown – LS:A0LCUL
The article provides a revenue breakdown for Catalyst Pharmaceuticals, Inc. (A0LCUL). Last year, the company generated 501.32 million EUR, with the Drug Products segment contributing 501.48 million EUR. The United States was the primary source of revenue, accounting for 501.48 million EUR.
CPRX|Catalyst Pharmaceuticals Inc|Price:31.490|
This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock price, market capitalization, P/E ratio, and upcoming earnings date. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, along with key financial indicators and historical quarterly and annual data. The report highlights revenue, EPS, net profit, net margin, gross margin, and various asset and liability figures, culminating in answers to frequently asked questions about the company's financial performance.
CPRX|Catalyst Pharmaceuticals Inc|Price:31.490|
Catalyst Pharmaceuticals Inc (CPRX) is a commercial-stage biopharmaceutical company focusing on rare diseases, with strong fundamentals and high growth potential. The stock is currently trading at $31.49, considered fairly valued, and analysts have a "Buy" rating with a target price of $33.542. The company markets FIRDAPSE, FYCOMPA, and AGAMREE, demonstrating steady revenue growth and leading industry net income.
Catalyst Pharmaceuticals | 8-K/A: Current report (Amendment)
This article is a current report amendment (8-K/A) for Catalyst Pharmaceuticals. It indicates a public filing of a document related to the company's financial or operational activities.
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) leaves Nasdaq after cash reserves reduce deal multiple
Angelini Pharma has finalized its $4.1 billion all-cash acquisition of Catalyst Pharmaceuticals, Inc. at $31.50 per share, leading to Catalyst's delisting from Nasdaq. The deal values Catalyst's enterprise at 5.1 times its expected 2026 revenue, a figure significantly influenced by Catalyst's substantial cash reserves and lack of funded debt. Key products Firdapse and Agamree, which contributed 91% of first-quarter product revenue, were central to the acquisition, with a royalty rate adjustment on Firdapse highlighting Angelini's strategic interest.
Catalyst Pharmaceuticals (NASDAQ:CPRX) departs Nasdaq as merger spread narrows to one cent
Catalyst Pharmaceuticals has been delisted from Nasdaq after its acquisition by Angelini Pharma was finalized on July 15, with each share exchanged for $31.50 in cash. The merger spread narrowed to just one cent by the final trading day, though a significant portion of the takeover gains had already been accounted for in the stock price before the official announcement. The article also notes Catalyst's financial performance prior to the sale, including a 5.6% increase in Q1 revenue.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, strengthening its presence in the U.S. market and leadership in Brain Health and Rare Diseases. The transaction involved investments from funds managed by Blackstone and CDP Equity, aiming to accelerate Angelini Pharma's global expansion and increase R&D investments. Catalyst, now a wholly-owned subsidiary, will form Angelini Pharma's Global Rare Disease Business Unit, with its common stock ceasing trading on Nasdaq.
Catalyst Pharmaceuticals (NASDAQ: CPRX) director equity converted to cash at $31.50
Catalyst Pharmaceuticals director Tamar Thompson has disposed of all her reported equity positions in the company, including common stock, restricted stock units, and stock options. This conversion to cash was triggered by the acquisition of Catalyst Pharmaceuticals by Angelini Pharma S.p.A. at a per-share price of $31.50, effective July 15, 2026.
Catalyst Pharma (CPRX) director cashes out stock and options in $31.50 Angelini buyout
Catalyst Pharmaceuticals director David S. Tierney has disposed of 383,314 shares of common stock at $31.50 per share following the acquisition of Catalyst Pharma by Angelini Pharma S.p.A. All of Tierney's reported RSUs and fully vested stock options were canceled and converted into cash at the $31.50 merger price, leaving him with no remaining holdings in these securities. The transaction, filed via Form 4, details the cash-out of various stock options and restricted stock units, emphasizing the complete exit of equity holdings by the director due to the merger.
Angelini deal converts CATALYST PHARMACEUTICALS (NASDAQ: CPRX) officer equity to cash
Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, reported the disposition of over 1 million shares of common stock at $31.50 per share due to the acquisition of Catalyst by Angelini Pharma S.p.A. All of Miller's restricted stock units and stock options were also canceled and converted into cash rights based on the same $31.50 reference price. Following these transactions, Miller holds no shares or derivative securities in Catalyst Pharmaceuticals.
Catalyst Pharma (NASDAQ: CPRX) CSO’s shares and options canceled in merger
Catalyst Pharmaceuticals' Chief Strategy Officer, Preethi Sundaram, disposed of 54,804 common shares at $31.50 per share and had all RSUs and stock options canceled. These transactions occurred on July 15, 2026, as part of the company's acquisition by Angelini Pharma S.p.A. As a result, Sundaram no longer holds common or derivative equity in Catalyst Pharmaceuticals.
Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?
Catalyst Pharmaceuticals (CPRX) has seen a significant 4.6x return over the past five years, and its current stock price appears to be roughly in line with its fundamental valuation. The company trades at a P/E ratio of about 17.4x, which is close to the estimated fair P/E of 17.0x and the biotech industry average. While the recent acquisition by Angelini Pharma could offer confidence, the future performance will depend on how the integration affects Catalyst Pharmaceutical's earnings and capital allocation.
Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?
Catalyst Pharmaceuticals stock has seen a significant 4.6x return over the past five years, yet its current valuation appears to be roughly in line with its fundamentals rather than being clearly cheap or overvalued. The company's P/E ratio of 17.4x is close to its estimated fair P/E of 17.0x and the biotech industry average, suggesting a fair pricing. Following its acquisition by Angelini Pharma, future returns for Catalyst Pharmaceuticals will likely depend on how the ownership influences earnings and capital allocation, as the "easy phase" of re-rating seems to be over.
Can Catalyst Pharmaceuticals (CPRX) Keep Looking Fairly Valued Now?
Catalyst Pharmaceuticals (CPRX) has seen significant returns over the past five years, but its current valuation suggests it's neither clearly cheap nor overvalued based on fundamentals. The stock trades at a P/E ratio of 17.4x, close to its estimated fair P/E and the biotech industry average. The acquisition by Angelini Pharma introduces new factors, meaning future returns will largely depend on how the integration impacts earnings and capital allocation, rather than a clear market opportunity.
[EFFECT] CATALYST PHARMACEUTICALS, INC. SEC Filing
This article announces an SEC filing for Catalyst Pharmaceuticals, Inc. (CPRX) labeled as an "EFFECT" filing, with a neutral impact and sentiment according to AI analysis. The filing, with effectiveness date July 16, 2026, was accepted by SEC EDGAR on July 17, 2026. The article also provides company overview, recent news, latest SEC filings, and stock data for CPRX.
[EFFECT] CATALYST PHARMACEUTICALS, INC. SEC Filing
This article announces an SEC Filing (Form EFFECT) by Catalyst Pharmaceuticals, Inc. (CPRX), indicating regulatory approval. The filing, dated July 16, 2026, details its effectiveness and provides basic company information and stock performance metrics. It also lists recent news and other SEC filings related to the company.
Catalyst Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing
Catalyst Pharmaceuticals has informed Nasdaq of its intention to delist its common stock following a merger. Trading in CPRX shares will be suspended on July 16, 2026, and the company plans to file a Form 15 to terminate registration and suspend reporting obligations after the Form 25 becomes effective. This action follows an SEC filing dated July 15, 2026.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals, significantly expanding its presence in the U.S. market and strengthening its global leadership in Brain Health and Rare Diseases. The deal, supported by Blackstone and CDP Equity, involves a total equity value of approximately $4.1 billion for Catalyst and aims to further Angelini Pharma's strategic vision for global growth, research and development investments, and a patient-centric approach. Catalyst's product portfolio and commercial infrastructure will be integrated into Angelini Pharma, with Italy remaining a key production and scientific hub.
Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA
Angelini has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals (NASDAQ:CPRX), valuing the company at roughly 9 times its estimated 2026 EBITDA. Catalyst investors received $31.50 per share in cash, a price that, when adjusted for Catalyst's estimated $861 million net cash, implies an operating value of $3.24 billion. The deal positions Angelini to become a major player in neurological rare diseases, leveraging Catalyst's Firdapse and Agamree revenue streams, despite future projections indicating a decline in Firdapse sales by 2035.
Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock
Nasdaq has initiated the process to delist Catalyst Pharmaceuticals' (CPRX) common stock from the Nasdaq Stock Market LLC, as indicated by a Form 25 notification filed under Section 12(b) of the Exchange Act. This action signifies that Nasdaq has followed its rules to remove the securities from listing and registration. The delisting could significantly reduce trading liquidity and general accessibility for investors.
Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board
Catalyst Pharmaceuticals (CPRX) stockholders have approved a merger agreement, leading to the resignation of all current directors once the transaction is complete. The stock has seen significant gains, with a 90-day return of 20.16% and a 5-year return of 461.96%, partly due to clinical updates for AGAMREE and vamorolone. Despite being valued at $31.67 per share, close to its last close, the company is framed as significantly undervalued compared to its modeled future cash flows, underpinned by a strong balance sheet and disciplined pipeline strategy.
Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care
Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) was removed from the S&P 600 Health Care sector index on July 14, 2026, as reported by S&P Capital IQ. The company is a biopharmaceutical firm focused on developing and commercializing medicines for rare diseases, including FIRDAPSE, FYCOMPA, and AGAMREE. This adjustment is part of several index removals for Catalyst Pharmaceuticals, also affecting other S&P and Russell indices.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Catalyst Pharmaceuticals stockholders have approved the company's merger with Angelini Pharma, where Catalyst will become a wholly owned subsidiary of Angelini Pharma. The merger proposal passed with the required majority vote at a special meeting on July 8, 2026. While an advisory compensation proposal did not receive stockholder approval, it was not a condition for the merger's completion.
Solaris Energy gets S&P SmallCap 600 spot as Catalyst exits
Solaris Energy Infrastructure (SEI) will be added to the S&P SmallCap 600 index on July 15, 2026, replacing Catalyst Pharmaceuticals (CPRX). Catalyst Pharmaceuticals is being removed from the index due to its acquisition by Angelini Pharma. This change impacts index funds and provides Energy sector representation in the S&P SmallCap 600.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Catalyst Pharmaceuticals stockholders have approved the company’s merger with Angelini Pharma S.p.A. at a virtual special meeting. The merger agreement will result in Catalyst becoming a wholly owned subsidiary of Angelini Pharma. Although an advisory proposal on executive compensation failed, it was non-binding and did not impact the merger's approval.
Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion
Solaris Energy Infrastructure Inc. is set to replace Catalyst Pharmaceuticals Inc. in the S&P SmallCap 600 index on July 15, 2026. This change is prompted by Angelini Pharma's impending acquisition of Catalyst Pharmaceuticals. The shuffle signifies shifts within the small-cap market and investors tracking the index should take note.
Catalyst Pharmaceuticals (CPRX) Proxy filing Summary
A special meeting is scheduled for July 8, 2026, for Catalyst Pharmaceuticals (CPRX) shareholders to vote on a proposed merger with Angelini Pharma S.p.A. Shareholders will receive $31.50 per share in cash, representing a 21% premium to the unaffected closing share price. The board and executives unanimously recommend voting in favor of the merger and related proposals.
Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary
Catalyst Pharmaceuticals (CPRX) reported a strong Q1 2025, with net revenues increasing 43.6% year-over-year to $141.4 million, driven by FIRDAPSE and the successful launch of AGAMREE. Net income more than doubled to $56.7 million. The company reaffirmed its full-year 2025 revenue guidance of $545 million-$565 million and maintains a robust cash position, with strategic plans for portfolio expansion.
Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal
Catalyst Pharmaceuticals' stockholders have approved the merger agreement with Angelini Pharma, where Catalyst will become a wholly-owned subsidiary of Angelini. While the merger proposal received overwhelming support, a non-binding advisory proposal for merger-related executive compensation was not approved, though this does not impact the merger's completion. The transaction remains subject to customary closing conditions and regulatory approvals.
Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary
This article provides a summary of Catalyst Pharmaceuticals (CPRX) Extraordinary General Meeting (EGM) held on July 8, 2026. Key aspects covered include meeting procedures, board introductions, corporate governance, and confirmation of quorum. The summary also references other recent events for Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data
Catalyst Pharmaceuticals (CPRX) stock appears fairly valued following positive Phase 1 data for Agamree and progress with the Angelini Pharma acquisition. The stock's P/E ratio is currently in line with both the biotech sector average and its implied fair ratio, suggesting it is neither a clear bargain nor overvalued. Future valuation will largely depend on the company's ability to translate these opportunities into sustained earnings growth.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals (CPRX) reported positive Phase I results for Agamree, suggesting its potential for new indications beyond Duchenne muscular dystrophy (DMD). The study indicated that Agamree offers corticosteroid benefits with less immunosuppression compared to PTC Therapeutics' Emflaza, which could lead to its use in other chronic inflammatory rare diseases. This development is significant as Catalyst Pharmaceuticals is in the process of being acquired by Angelini Pharma for $4.1 billion, with the deal expected to close in Q3 2026.
CPRX - Catalyst Pharmaceuticals Inc Earnings
This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock performance, key financial metrics, earnings data, and insider/institutional ownership. It highlights the company's strong growth in sales and EPS over various periods and offers analyst recommendations.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE® conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy adult volunteers showed that AGAMREE® delivers glucocorticoid and anti-inflammatory activity with less pronounced immunosuppressive biomarker effects at clinical doses, suggesting potential for treating a broad range of chronic inflammatory rare diseases. Significant immunosuppressive effects were only observed at the highest dose levels, exceeding currently approved AGAMREE® dosing for Duchenne muscular dystrophy.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE® conducted by Catalyst Pharmaceuticals, indicating the drug's potential for broad chronic inflammatory rare diseases by demonstrating glucocorticoid and anti-inflammatory activity without significant immunosuppressive effects at therapeutic doses. The study found AGAMREE® to have comparable cortisol suppression to deflazacort at clinical doses but with less pronounced immunosuppressive biomarker effects. This supports its differentiated safety profile observed in long-term studies for Duchenne muscular dystrophy (DMD), where it showed advantages in bone health and growth compared to conventional corticosteroids.
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Santhera Pharmaceuticals has announced topline results from a Phase 1 clinical study of AGAMREE® conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy volunteers indicates that AGAMREE® delivers glucocorticoid and anti-inflammatory activity with minimal immunosuppressive effects, suggesting its potential for treating various chronic inflammatory rare diseases. These findings support its current use for Duchenne muscular dystrophy and future indications, with findings showing immunosuppressive effects only at doses higher than those approved.
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression
Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no significant immunosuppressive activity at clinical doses, supporting its current dosing for Duchenne muscular dystrophy. These findings suggest vamorolone could be a differentiated treatment option for a wide range of chronic inflammatory rare diseases by providing anti-inflammatory benefits without the typical immunosuppression of conventional corticosteroids.
Vamorolone Demonstrates On-Target Glucocorticoid Activity
Catalyst Pharmaceuticals, Inc. announced positive topline results from a Phase 1 clinical study of vamorolone in healthy adult volunteers. The study showed that vamorolone delivers on-target glucocorticoid and anti-inflammatory activity with expected cortisol suppression, but without significant immunosuppression at clinical doses. These findings suggest vamorolone distinguishes itself from traditional corticosteroids and has potential for treating various chronic inflammatory rare diseases.
Catalyst's rare-disease steroid showed immune activity without the usual suppression
Catalyst Pharmaceuticals announced positive topline results from a Phase 1 study of vamorolone in healthy adults, demonstrating on-target glucocorticoid activity with expected cortisol suppression and without significant immunosuppression at clinical doses. The study compared vamorolone to deflazacort, showing similar cortisol suppression but less pronounced immunosuppressive effects for vamorolone. These findings support vamorolone's potential use in Duchenne muscular dystrophy (DMD) and other chronic inflammatory rare diseases by offering anti-inflammatory benefits without the typical immune-suppressing side effects of conventional corticosteroids.
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In
Catalyst Pharmaceuticals (CPRX) has generated significant investor interest due to its strong rare-disease portfolio, which produced substantial annual revenue and net income. While the current share price of $31.42 is close to an external target, cash flow estimates suggest a 50% discount to its intrinsic value, implying potential upside. However, its P/E ratio is slightly above the industry average, raising questions about whether future growth is already priced in.
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article provides access to the "Price to earnings forward" financial data for Catalyst Pharmaceuticals, Inc. (CPRX) on the Nasdaq Stock Market. It's presented through the TradingView platform, which offers various financial tools and market data services. The content emphasizes accessing specific financial metrics for the company.
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article displays information regarding the enterprise value to revenue forward for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It provides a snapshot of the company's financial data on TradingView. The content is primarily a data point without extensive analytical text.
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX
This article provides the "Price to sales forward" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems focused on delivering this specific financial data point.
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026
As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sentiment for CPRX among investors.
Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger
Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still contingent on shareholder approval and is expected to close in Q3 2026. The merger will see Catalyst operate as a wholly-owned subsidiary of Angelini, shifting the investment focus for Catalyst shareholders from long-term independent growth to a defined cash outcome.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair to shareholders. KSF encourages shareholders who believe the offer undervalues Catalyst Pharmaceuticals to contact them for a discussion regarding their legal rights.
